Compare · CVRX vs DXCM
CVRX vs DXCM
Side-by-side comparison of CVRx Inc. (CVRX) and DexCom Inc. (DXCM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CVRX and DXCM operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $28.31B, about 218.6x CVRX ($129.5M).
- Over the past year, CVRX is down 41.8% and DXCM is down 18.0% - DXCM leads by 23.8 points.
- DXCM has been more active in the news (6 items in the past 4 weeks vs 1 for CVRX).
- DXCM has more recent analyst coverage (25 ratings vs 13 for CVRX).
- Company
- CVRx Inc.
- DexCom Inc.
- Price
- $4.87+1.88%
- $73.36+2.55%
- Market cap
- $129.5M
- $28.31B
- 1M return
- -7.50%
- +6.92%
- 1Y return
- -41.82%
- -18.05%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- 2005
- News (4w)
- 1
- 6
- Recent ratings
- 13
- 25
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Latest CVRX
- CVRx to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call on August 6, 2026
- CVRx Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- CVRx Announces Chief Financial Officer Transition
- Director Nielsen Kirk G. was granted 8,720 shares (SEC Form 4)
- Director Jain Mudit K. was granted 8,720 shares, increasing direct ownership by 154% to 14,370 units (SEC Form 4)
- Director Slattery Joseph P was granted 8,720 shares, increasing direct ownership by 28% to 39,365 units (SEC Form 4)
- Director Hill, Mitch C. was granted 8,720 shares (SEC Form 4)
- Director Ballinger Kevin J. was granted 8,720 shares (SEC Form 4)
- Director Shadan Martha was granted 8,720 shares (SEC Form 4)
- Director Dale Michael D was granted 29,005 shares (SEC Form 4)
Latest DXCM
- Dexcom Announced as First Participant Selected for FDA's TEMPO Digital Health Devices Pilot Program
- Executive Chair Sayer Kevin R sold $2,041,999 worth of shares (26,756 units at $76.32) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 328,970 units (SEC Form 4)
- EVP Chief Legal Compliance Off Brown Michael Jon sold $126,514 worth of shares (1,700 units at $74.42) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 104,653 units (SEC Form 4)
- Dexcom G7 15 Day Receives Health Canada Authorization: Extending Wear and Continuity for Canadian Adults Living with Diabetes
- Dexcom Schedules Second Quarter 2026 Earnings Release and Conference Call for July 30, 2026 at 4:30 p.m. Eastern Time
- Executive Chair Sayer Kevin R sold $1,926,432 worth of shares (26,756 units at $72.00) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 355,726 units (SEC Form 4)
- Dexcom Further Advances Vision of Glucose Biosensing for All
- Deutsche Bank initiated coverage on Dexcom with a new price target
- EVP Chief Legal Compliance Off Brown Michael Jon sold $128,435 worth of shares (1,700 units at $75.55) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 106,353 units (SEC Form 4)
- Director Foletta Mark G sold $296,540 worth of shares (4,000 units at $74.13) as part of a pre-agreed trading plan (SEC Form 4)